Education
About Us
Working with TipRanks
Follow Us
Climb Bio (CLYM)
NASDAQ:CLYM
CLYM Stock Chart & Stats
$1.73
-$0.15(-7.18%)
At close: 4:00 PM EST
$1.73
-$0.15(-7.18%)
Day’s Range― - ―
52-Week Range$1.05 - $3.30
Previous CloseN/A
Volume51.97K
Average Volume (3M)721.78K
Market Cap
$127.40M
Enterprise Value-$258.45K
Total Cash (Recent Filing)$86.90M
Total Debt (Recent Filing)$580.00K
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Mar 09, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding67,764,100
10 Day Avg. Volume1,217,427
30 Day Avg. Volume721,779
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.80
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$9.25Price Target Upside434.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe Phase II PrisMN study for pMN was initiated and is an open-label, dose-ranging study designed to identify a Phase III.
Product DevelopmentBudoprutug has already demonstrated strong proof-of-concept data in primary membranous nephropathy (pMN), an indication with blockbuster potential on its own.
Regulatory ApprovalClimb received regulatory clearance to initiate a Phase I trial of the APRIL antibody CLYM116 in healthy volunteers.
Bears Say
Comparative Analysis UncertaintyIt is still early to draw direct comparisons between budoprutug and other late-stage programs in pMN.
Valuation ConcernsThe opportunity of CLYM116 in IgAN is not currently included in the valuation for Climb, which is based solely on the potential of budoprutug in other conditions.
Climb Bio News
CLYM FAQ
What was Climb Bio’s price range in the past 12 months?
Climb Bio lowest stock price was $1.05 and its highest was $3.30 in the past 12 months.
What is Climb Bio’s market cap?
Climb Bio’s market cap is $127.40M.
When is Climb Bio’s upcoming earnings report date?
Climb Bio’s upcoming earnings report date is Mar 09, 2026 which is in 93 days.
How were Climb Bio’s earnings last quarter?
Climb Bio released its earnings results on Nov 06, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.147 by -$0.043.
Is Climb Bio overvalued?
According to Wall Street analysts Climb Bio’s price is currently Undervalued.
Does Climb Bio pay dividends?
Climb Bio does not currently pay dividends.
What is Climb Bio’s EPS estimate?
Climb Bio’s EPS estimate is -0.19.
How many shares outstanding does Climb Bio have?
Climb Bio has 67,764,100 shares outstanding.
What happened to Climb Bio’s price movement after its last earnings report?
Climb Bio reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.147. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of Climb Bio?
Currently, no hedge funds are holding shares in CLYM
Climb Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.25 (434.68% Upside)
$9.25 (434.68% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-60.28%
12-Months-Change
Fundamentals
Return on Equity
-25.65%
Trailing 12-Months
Asset Growth
-14.88%
Trailing 12-Months
CLYM Stock 12 Month Forecast
Average Price Target
$9.25
▲(434.68% Upside)
Technical Analysis
Agenus
―
TuHURA Biosciences
―
Ovid Therapeutics
―
Cognition Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
8.49% Insiders
2.53% Mutual Funds
56.39% Other Institutional Investors
30.18% Public Companies and Individual Investors
Options Prices
Currently, No data available
---